Cyclophosphamide, doxorubicin, and cisplatin combined in the treatment of advanced sarcomas

J. H. Edmonson, R. G. Hahn, A. J. Schutt, H. F. Bisel, J. N. Ingle

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Twenty-five patients with evaluable histologically confirmed inoperable metastatic sarcomas were treated once every four weeks with cyclophosphamide, doxorubicin, and cisplatin in dose of 400, 40, and 60 mg/m2, respectively. Cyclophosphamide and doxorubicin were given by rapid intravenous injection followed immediately by cisplatin by slow intraveneous infusion (2-6 hr) in 1 liter of 0.45% saline with mannitol added. Leukopenia, alopecia, and vomiting were common side effects and three patients refused further treatment because of vomiting following their initial courses. No drug-related deaths occurred and we removed no one from the study because of toxicity problems. Among the 9 patients who experienced objective tumor regression were 2 of 2 with hemangiosarcoma, 3 of 5 with malignant fibrous histiocytoma, 3 of 5 with osteosarcoma, and 1 of 1 with pleomorphic liposarcoma of bone. Although not therapeutically gratifying, these results appear to be better than any previously observed at our institution.

Original languageEnglish (US)
Pages (from-to)319-321
Number of pages3
JournalMedical and Pediatric Oncology
Volume11
Issue number5
StatePublished - 1983

Fingerprint

Sarcoma
Doxorubicin
Cyclophosphamide
Cisplatin
Vomiting
Malignant Fibrous Histiocytoma
Liposarcoma
Hemangiosarcoma
Alopecia
Leukopenia
Mannitol
Osteosarcoma
Intravenous Injections
Therapeutics
Bone and Bones
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Cite this

Edmonson, J. H., Hahn, R. G., Schutt, A. J., Bisel, H. F., & Ingle, J. N. (1983). Cyclophosphamide, doxorubicin, and cisplatin combined in the treatment of advanced sarcomas. Medical and Pediatric Oncology, 11(5), 319-321.

Cyclophosphamide, doxorubicin, and cisplatin combined in the treatment of advanced sarcomas. / Edmonson, J. H.; Hahn, R. G.; Schutt, A. J.; Bisel, H. F.; Ingle, J. N.

In: Medical and Pediatric Oncology, Vol. 11, No. 5, 1983, p. 319-321.

Research output: Contribution to journalArticle

Edmonson, JH, Hahn, RG, Schutt, AJ, Bisel, HF & Ingle, JN 1983, 'Cyclophosphamide, doxorubicin, and cisplatin combined in the treatment of advanced sarcomas', Medical and Pediatric Oncology, vol. 11, no. 5, pp. 319-321.
Edmonson, J. H. ; Hahn, R. G. ; Schutt, A. J. ; Bisel, H. F. ; Ingle, J. N. / Cyclophosphamide, doxorubicin, and cisplatin combined in the treatment of advanced sarcomas. In: Medical and Pediatric Oncology. 1983 ; Vol. 11, No. 5. pp. 319-321.
@article{3f1fcd0cbb6a48c283cecee4713a58de,
title = "Cyclophosphamide, doxorubicin, and cisplatin combined in the treatment of advanced sarcomas",
abstract = "Twenty-five patients with evaluable histologically confirmed inoperable metastatic sarcomas were treated once every four weeks with cyclophosphamide, doxorubicin, and cisplatin in dose of 400, 40, and 60 mg/m2, respectively. Cyclophosphamide and doxorubicin were given by rapid intravenous injection followed immediately by cisplatin by slow intraveneous infusion (2-6 hr) in 1 liter of 0.45{\%} saline with mannitol added. Leukopenia, alopecia, and vomiting were common side effects and three patients refused further treatment because of vomiting following their initial courses. No drug-related deaths occurred and we removed no one from the study because of toxicity problems. Among the 9 patients who experienced objective tumor regression were 2 of 2 with hemangiosarcoma, 3 of 5 with malignant fibrous histiocytoma, 3 of 5 with osteosarcoma, and 1 of 1 with pleomorphic liposarcoma of bone. Although not therapeutically gratifying, these results appear to be better than any previously observed at our institution.",
author = "Edmonson, {J. H.} and Hahn, {R. G.} and Schutt, {A. J.} and Bisel, {H. F.} and Ingle, {J. N.}",
year = "1983",
language = "English (US)",
volume = "11",
pages = "319--321",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Cyclophosphamide, doxorubicin, and cisplatin combined in the treatment of advanced sarcomas

AU - Edmonson, J. H.

AU - Hahn, R. G.

AU - Schutt, A. J.

AU - Bisel, H. F.

AU - Ingle, J. N.

PY - 1983

Y1 - 1983

N2 - Twenty-five patients with evaluable histologically confirmed inoperable metastatic sarcomas were treated once every four weeks with cyclophosphamide, doxorubicin, and cisplatin in dose of 400, 40, and 60 mg/m2, respectively. Cyclophosphamide and doxorubicin were given by rapid intravenous injection followed immediately by cisplatin by slow intraveneous infusion (2-6 hr) in 1 liter of 0.45% saline with mannitol added. Leukopenia, alopecia, and vomiting were common side effects and three patients refused further treatment because of vomiting following their initial courses. No drug-related deaths occurred and we removed no one from the study because of toxicity problems. Among the 9 patients who experienced objective tumor regression were 2 of 2 with hemangiosarcoma, 3 of 5 with malignant fibrous histiocytoma, 3 of 5 with osteosarcoma, and 1 of 1 with pleomorphic liposarcoma of bone. Although not therapeutically gratifying, these results appear to be better than any previously observed at our institution.

AB - Twenty-five patients with evaluable histologically confirmed inoperable metastatic sarcomas were treated once every four weeks with cyclophosphamide, doxorubicin, and cisplatin in dose of 400, 40, and 60 mg/m2, respectively. Cyclophosphamide and doxorubicin were given by rapid intravenous injection followed immediately by cisplatin by slow intraveneous infusion (2-6 hr) in 1 liter of 0.45% saline with mannitol added. Leukopenia, alopecia, and vomiting were common side effects and three patients refused further treatment because of vomiting following their initial courses. No drug-related deaths occurred and we removed no one from the study because of toxicity problems. Among the 9 patients who experienced objective tumor regression were 2 of 2 with hemangiosarcoma, 3 of 5 with malignant fibrous histiocytoma, 3 of 5 with osteosarcoma, and 1 of 1 with pleomorphic liposarcoma of bone. Although not therapeutically gratifying, these results appear to be better than any previously observed at our institution.

UR - http://www.scopus.com/inward/record.url?scp=0021075954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021075954&partnerID=8YFLogxK

M3 - Article

C2 - 6355797

AN - SCOPUS:0021075954

VL - 11

SP - 319

EP - 321

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 5

ER -